Development and approval of Project Proposal Sample Clauses

The 'Development and approval of Project Proposal' clause outlines the process by which a project proposal is created, reviewed, and formally accepted by the relevant parties. Typically, this clause specifies the responsibilities for drafting the proposal, the timeline for submission, and the criteria or procedures for review and approval. For example, it may require the contractor to submit a detailed plan for client review, with approval needed before work can commence. The core function of this clause is to ensure that all parties agree on the project's scope and objectives before any substantive work begins, thereby reducing misunderstandings and aligning expectations.
Development and approval of Project Proposal. (a) If RTA approves the scope of work under clause 5.1(d)(i), we will prepare and deliver to RTA a Project Proposal for the Alliance Works within 60 Business Days after the date on which RTA notifies us in writing that it has approved the scope of work under clause 5.1(d)(i) or such other period agreed in writing by RTA. (b) Following receipt of the Project Proposal, RTA may, in its discretion, elect to: (i) approve the Project Proposal by notice in writing to the NOPs; (ii) request the Participants to amend the Project Proposal and re-submit it to RTA for approval in accordance with this clause 5.2(b); or (iii) give the ALT a notice in writing informing the ALT that the Alliance Works will not proceed, in which case, clause 11.1(a) will apply on and from the date of that notice.
View SourceView Similar (4)
Development and approval of Project Proposal. (a) Where it is agreed that Coffs CityWorks will undertake a Stage of the Alliance Works, we will prepare and deliver to RTA a Project Proposal for that Stage of the Alliance Works by a date agreed in writing by RTA. (b) Following receipt of the Project Proposal, RTA may, in its discretion, elect to: (i) approve the Project Proposal by notice in writing to Council; (ii) request the Participants to amend the Project Proposal and re-submit it to RTA for approval in accordance with this clause 5.4; or (iii) give the ALT a notice in writing informing the ALT that the Alliance Works will not proceed, in which case, clause 11.1(a) will apply on and from the date of that notice.
View Source
Development and approval of Project Proposal. (a) We will prepare and deliver a Project Proposal to TIDC within 80 Business Days after the date on which TIDC notifies us in writing that it has approved the Scope of Work under clause 6.4(c)(i) or such other period agreed in writing by TIDC at the request of the ALT. (b) The Project Proposal will include: (i) a fully detailed TCE, including a separate calculation for each Portion and the proposed lump sum seed funds for the Schedule Performance Pool and the KRA Performance Pool; (ii) a fully detailed construction programme, which includes a construction staging methodology, outline of the work to be undertaken in each Possession and the proposed Dates for Completion; (iii) those fully documented components of the AMP identified in Schedule 8 which are required to be submitted by this stage of the Project; (iv) confirmation that all concerns raised by the Stakeholders have been satisfactorily considered and addressed or can be addressed; (v) confirmation that all necessary Approvals have been or can be obtained; (vi) a Value for Money Report; (vii) a certificate from the Independent Estimator that the TCE is fair and reasonable; and (viii) the information referred to in clause 9.8(b) (Industrial Relations). (c) Following receipt of the Project Proposal TIDC may, in its absolute discretion, elect to: (i) approve the Project Proposal by notice in writing to the NOPs; (ii) request the Participants to amend the Project Proposal and re-submit it to TIDC for approval in accordance with clause 6.5(b); or (iii) give the ALT a notice in writing informing the ALT that the Alliance Activities will not proceed, in which case clause 16.1(a) will apply on and from the date of that notice. (d) We will provide all documents, access and assistance necessary for the Independent Estimator to audit the TCE.
View Source

Related to Development and approval of Project Proposal

  • New Project Approval Consultant and District recognize that Consultant’s Services may include working on various projects for District. Consultant shall obtain the approval of District prior to the commencement of a new project.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Project Approval The County may issue a Job Order Authorization for the Work, to include the firm-fixed-price of the Job Order and the project duration. Contractor agrees that all clauses of this Contract are applicable to any Job Order issued hereunder. The County reserves the right to reject a Contractor’s Quote based on unjustifiable quantities and/or methods, performance periods, inadequate documentation, or other inconsistencies or deficiencies on the Contractor’s part in the sole opinion of the County. The County reserves the right to issue a unilateral Job Order authorization for the Work if a Quote price cannot be mutually agreed upon. This is based upon unjustifiable quantities in the sole opinion of the County. The County also reserves the right to not issue a Job Order Authorization if the County’s requirement is no longer valid or the project is not funded. In these instances, the Contractor has no right of claim to recover Quote expenses. The County may pursue continuing valid requirements by other means where Contract was not reached with the Contractor.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.